Skip to content
Open access

Patient characteristics, treatment patterns, and survival across estrogen receptor expression subgroups in HER2-negative breast cancer: a population-based cohort study

Aug 2026 · The Lancet Regional Health - Europe · Vol 68, pp. 101826 · 0 citations · 26 references
Medicine

TL;DR

The findings highlight the importance of assessment of ER-low, mild and moderate tumors (1–59%) and report ER as a percentage can provide additional biological insight in clinical decision-making.

Abstract

Summary Background Estrogen receptor (ER) low (1–9%) breast cancer (BC) often behaves like triple-negative BC, while ERhigh (≥60%) disease has a more favorable prognosis. However, tumors with ER expressing 10–59% represent a poorly defined patient population. In this nationwide cohort study, we aimed to describe real-world patient characteristics, treatment patterns and survival across the entire ER spectrum in Human Epidermal growth factor Receptor 2 (HER2)-negative BC. Methods We conducted a population-based cohort study of all women diagnosed with HER2-negative BC in Sweden (2007–2023), based on prospectively collected data. Tumors were stratified into five ER subgroups: ER0% (ERzero), ER1–9% (ERlow), ER10–29% (ERmild), ER30–59% (ERmod), and ER60–100% (ERhigh). We evaluated overall survival (OS) by ER subgroups and treatment (chemotherapy [CT] and endocrine therapy [ET]) using Kaplan–Meier analysis and multivariable Cox regression. Findings We included 75,211 patients. Compared to the ERhigh subgroup, both the ERmild (adjusted HR [aHR] = 1.59, 95% confidence interval [CI]: 1.31–1.93) and ERmod (aHR = 1.31, 95% CI: 1.17–1.47) subgroups had significantly worse survival (both adjusted P [aP] < 0.001). Notably, ERmild patients had survival outcomes and molecular characteristics similar to those of ERlow and ERzero patients. Patients with ERmild (aHR = 0.46, 95% CI: 0.23–0.94, aP = 0.033) and ERmod (aHR = 0.60, 95% CI: 0.42–0.85, aP = 0.0046) tumors, CT + ET was associated with a lower risk of death than ETonly. Interpretation Our findings highlight the importance of assessment of ER-low, mild and moderate tumors (1–59%). Reporting ER as a percentage can provide additional biological insight in clinical decision-making. Funding This study received no external funding.

Read PDF

Similar papers

Open access Sep 2026

Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registries

Background Hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) tumors are the most prevalent subtypes of early breast cancer (eBC). Despite the generally favorable prognosis, a relevant proportion experiences invasive disease events following surgery. We aimed t...

P. Grieger, M. Y. Beykloo, C. Lee et al. · 0 citations
Open access Sep 2026

A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy

The findings reinforce the high unmet need in patients with HR+/HER2’s metastatic breast cancer whose disease has become resistant to ET, highlighting the need for effective treatments in this setting.

J. O'Shaughnessy, M. Rehnquist, N. Sadetsky et al. · 0 citations
Review Open access Aug 2026

Endocrine therapy in early-stage estrogen Receptor-Low breast cancer: a systematic review and Meta-Analysis.

BACKGROUND Tumors with ≥1% estrogen receptor (ER) expression by immunohistochemistry (IHC) are classified as hormone receptor-positive. While this definition includes ER-low tumors (ER 1-9%), the clinical benefit of endocrine therapy (ET) in ER-low early-stage breast cancer (BC) remains uncertain. METHODS This is a s...

D. Massa, E. Chiappe, V. Delucchi et al. · 0 citations
Open access Sep 2026

Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024

The findings highlight the clinical relevance of ESR1m emergence prior to progression and underscore the need for strategies to better identify and manage patients with emerging endocrine resistance.

J. Meisel, Clara Chen, A. Kris et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.